<?xml version="1.0" encoding="UTF-8"?>
<ack id="ceack10">
 <sec>
  <title>Acknowledgments</title>
  <p>Primary financial support was from 
   <funding-source id="GS1">Cancer Research UK</funding-source> [C1298/A10410]. Unrestricted educational grants from Celgene Corporation, Amgen and Merck Sharp and Dohme, and funding from Myeloma UK supported trial coordination and laboratory studies. We thank all the patients at centres throughout the UK whose willingness to participate made this study possible. We are grateful to the UK National Cancer Research Institute Haematological Oncology Clinical Studies Group; UK Myeloma Research Alliance; and all principal investigators, subinvestigators, and local centre staff for their dedication and commitment to recruiting patients to the study. We thank members of the Myeloma XI Trial Steering Committee and Data Monitoring and Ethics Committee. The support of the Clinical Trials Research Unit at the University of Leeds (UK) was essential to the successful running of the study; we thank all their staff who have contributed, past and present. Central laboratory analysis was done at the Institute of Immunology and Immunotherapy, University of Birmingham (UK); the Institute of Cancer Research, London (UK); and the Haematological Malignancy Diagnostic Service, St James's University Hospital, Leeds. We are very grateful to the laboratory teams for their contribution to the study. We also acknowledge support from the National Institute of Health Biomedical Research Centre at the Royal Marsden Hospital (London) and the Institute of Cancer Research. The authors received editorial support from Excerpta Medica, funded by the University of Leeds.
  </p>
 </sec>
</ack>
